Canopus BioPharma Inc. announces positive results from an In-Vitro live Ebola Virus study | Publicwire

Canopus BioPharma Inc. (OTC Pink: CBIA) today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.
http://bit.ly/1GZZZ1A